Regeneron-backed Parabilis surges after record-setting IPO
Seeking Alpha News (Wed, 10-Jun 1:30 PM ET)
TipRanks (Tue, 9-Jun 7:16 AM ET)
TipRanks (Tue, 9-Jun 6:05 AM ET)
TipRanks (Tue, 9-Jun 5:10 AM ET)
Tango soars on early-stage data for vopimetostat in pancreatic cancer
Seeking Alpha News (Mon, 8-Jun 10:59 AM ET)
Bernstein Remains a Hold on Revolution Medicines (RVMD)
TipRanks (Mon, 8-Jun 7:16 AM ET)
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Globe Newswire (Wed, 3-Jun 8:30 AM ET)
Globe Newswire (Sun, 31-May 8:06 AM ET)
Globe Newswire (Thu, 21-May 4:05 PM ET)
Globe Newswire (Wed, 6-May 6:00 PM ET)
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Revolution Medicines trades on the NASDAQ stock market under the symbol RVMD.
As of June 10, 2026, RVMD stock price declined to $144.19 with 3,037,323 million shares trading.
RVMD has a beta of 2.14, meaning it tends to be more sensitive to market movements. RVMD has a correlation of 0.14 to the broad based SPY ETF.
RVMD has a market cap of $30.65 billion. This is considered a Large Cap stock.
Last quarter Revolution Medicines reported $0 in Revenue and -$2.29 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.45.
In the last 3 years, RVMD traded as high as $166.50 and as low as $15.44.
The top ETF exchange traded funds that RVMD belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
RVMD has outperformed the market in the last year with a return of +255.3%, while the SPY ETF gained +22.2%. In the last 3 month period, RVMD beat the market returning +44.5%, while SPY returned +7.2%. However, in the most recent 2 weeks RVMD has underperformed the stock market by returning -6.9%, while SPY returned -3.4%.
RVMD support price is $145.61 and resistance is $153.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVMD shares will trade within this expected range on the day.
